Standard BioTools (LAB) Stock Price, News & Analysis

Company Overview

Standard BioTools Inc. (NASDAQ: LAB) develops and supplies technologies used to advance biomedical research, with a focus on single-cell analysis, spatial biology and proteomics. Its products are designed to help researchers characterize cells, tissues and biological samples at high resolution for applications including immunology, oncology, infectious disease research and drug development.

The company’s portfolio includes mass cytometry systems and reagents sold under the CyTOF and Maxpar brands, as well as imaging technologies for analyzing the spatial distribution of proteins and other biomarkers in tissue samples. Standard BioTools also provides microfluidic and single-cell analysis platforms, consumables, software and related services. Through its combination with SomaLogic, the company also offers the SomaScan proteomics platform, which enables broad protein biomarker measurement from biological samples.

Standard BioTools was formerly known as Fluidigm and adopted its current name following the completion of its combination with SomaLogic in 2023. The company serves academic institutions, pharmaceutical and biotechnology companies, clinical research organizations and other laboratories internationally. Standard BioTools is headquartered in South San Francisco, California, and is led by President and Chief Executive Officer Michael Egholm.

Key Stats

• Today's Range: $0.71 to $0.74
• 50-Day Range: $0.64 to $0.90
• 52-Week Range: $0.63 to $1.72
• Volume: 1.59 million shs
• Average Volume: 2.47 million shs
• Market Capitalization: $290.74 million
• P/E Ratio: 3.37
• Dividend Yield: N/A
• Price Target: $1.35
• Consensus Rating: Reduce

Standard BioTools Stock Analysis - MarketRank™

Standard BioTools scored higher than 76% of companies evaluated by MarketBeat, and ranked 147th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Standard BioTools has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Standard BioTools has a consensus price target of $1.35, representing about 82.3% upside from its current price of $0.74.

Amount of Analyst Coverage

Standard BioTools has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Standard BioTools is 3.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of Standard BioTools is 3.37, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.02.

Price to Book Value per Share Ratio

Standard BioTools has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.90% of the float of Standard BioTools has been sold short.

Short Interest Ratio / Days to Cover

Standard BioTools has a short interest ratio ("days to cover") of 1.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Standard BioTools has recently decreased by 12.95%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Standard BioTools does not currently pay a dividend.

Dividend Growth

Standard BioTools does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.89

News Sentiment

Standard BioTools has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Standard BioTools this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for LAB on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Standard BioTools to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Standard BioTools insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.81% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:LAB
• Previous Symbol: NASDAQ:SLGC
• CIK: 1162194
• Web: www.standardbio.com
• Phone: (650) 266-6000
• Fax: 650-871-7152
• Employees: 389
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Standard BioTools: $1.35
• High Price Target: $1.35
• Low Price Target: $1.35
• Potential Upside/Downside: +82.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.22
• Trailing P/E Ratio: 3.37
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.90 million
• Net Margins: 100.36%
• Pretax Margin: -107.55%
• Return on Equity: -7.57%
• Return on Assets: -6.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.10
• Quick Ratio: 8.80

Sales & Book Value

• Annual Sales: $84.60 million
• Price / Sales: 3.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.10 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 392,579,000
• Free Float: 287,329,000
• Market Cap: $290.74 million
• Optionable: Optionable
• Beta: 1.37